Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

49 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Rutgeerts P, et al. Among authors: schaible tf. Gastroenterology. 1999 Oct;117(4):761-9. doi: 10.1016/s0016-5085(99)70332-x. Gastroenterology. 1999. PMID: 10500056 Clinical Trial.
Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, Spencer-Smith EA, Goldman AL, Roth SH, Toder JS, Warner D, Quinn A, Keenan GF, Schaible TF; PROMPT Study Group. Profiling Remicade Onset with MTX in a Prospective Trial. Shergy WJ, et al. Among authors: schaible tf. J Rheumatol. 2002 Apr;29(4):667-77. J Rheumatol. 2002. PMID: 11950005 Clinical Trial.
Long term safety of infliximab.
Schaible TF. Schaible TF. Can J Gastroenterol. 2000 Sep;14 Suppl C:29C-32C. doi: 10.1155/2000/698523. Can J Gastroenterol. 2000. PMID: 11023558
Infliximab for the treatment of fistulas in patients with Crohn's disease.
Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Present DH, et al. Among authors: schaible tf. N Engl J Med. 1999 May 6;340(18):1398-405. doi: 10.1056/NEJM199905063401804. N Engl J Med. 1999. PMID: 10228190 Clinical Trial.
49 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page